Arrowstreet Capital
LAB icon

Arrowstreet Capital’s Standard BioTools LAB Stock Holding History

Arrowstreet Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-429,883
Closed -$3.19M – 2424
2020
Q3 		$3.19M Sell
429,883
-361,490
-46% -$2.5M 0.01% 1355
2020
Q2 		$3.17M Buy
+791,373
New +$2.76M 0.01% 1254
2016
Q4 		– Sell
-51,901
Closed -$416K – 2130
2016
Q3 		$416K Buy
+51,901
New +$477K ﹤0.01% 1292
2014
Q1 		– Sell
-18,520
Closed -$710K – 1238
2013
Q4 		$710K Buy
18,520
+13,384
+261% +$394K ﹤0.01% 904
2013
Q3 		$113K Buy
+5,136
New +$101K ﹤0.01% 956

Other funds holding LAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Arrowstreet Capital's LAB Position: Q4 2020 in Review

Arrowstreet Capital sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 429,883 shares — an estimated $3.19M sold.

Arrowstreet Capital first reported a position in LAB in Q3 2013 and held it in 5 quarters. The position peaked at $3.19M in Q3 2020. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

  • Arrowstreet Capital reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 429,883 Standard BioTools shares in Q4 2020, an estimated $3.19M.
  • Arrowstreet Capital first reported a position in Standard BioTools in Q3 2013 and held it in 5 quarters.
  • Arrowstreet Capital's Standard BioTools position peaked at $3.19M in Q3 2020.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.